PTEN and neoplasm: The significant improvement in progression-free survival seen with fulvestrant and capivasertib versus placebo in the overall population was preserved in the non-altered group (0·56, 0·33–0·96, p=0·035), but not in patients with PI3K/PTEN pathway altered tumours (0·59, 0·34–1·03, p=0·064).